FDA approves eye drop for presbyopia, first drug treatment for age-related near-vision loss
Ryzumvi (phentolamine ophthalmic solution 0.75%) targets a condition affecting roughly 90% of U.S. adults over 45.
Stock Titan · +14 outlets
STAT+: Jury rules for ousted scientist David Sabatini, awards $6M in damages
Sabatini's career collapsed after a younger colleague accused him of inappropriate sexual conduct in his lab; a jury sided with him.
STAT · +2 outlets
Moderna shares drop 10% as profit-taking hits cancer vaccine rally
The pullback followed a steep 2026 run in Moderna stock tied to optimism around its mRNA cancer vaccine program.
24/7 Wall St. · +10 outlets
Vaccine stocks rally on report of NIH cancer-vaccine push
BioNTech, Novavax and Moderna led gains after reports the NIH is pursuing a cancer vaccine initiative.
Stocktwits · +10 outlets
STAT+: RevMed's pancreatic cancer drug nears European approval
European regulators recommended approval of Revolution Medicines' Rasonque for pancreatic cancer following a prior FDA green light.
STAT · +3 outlets
FDA advisers narrowly vote to add 6 peptides to drug compounding list
The vote advances an HHS plan to let compounding pharmacies produce certain peptides, a contested policy shift.
STAT · +5 outlets
BioNTech falls below €79 as BNT113 trial misses first hurdle
The trial setback weighed on BioNTech shares amid a broader vaccine-sector rally.
ad-hoc-news.de · +1 outlets
Lilly's amylin combo raises the bar for obesity drug developers
New data from the amylin-based combination lifts efficacy expectations across the competitive obesity field.
Drug Discovery News · +7 outlets
Estuary emerges from stealth with about $100M for kidney disease gene therapies
The Series A, led by RA Capital with Biogen backing, funds two genetic medicines for inherited ADPKD.
Biopharmadive · +3 outlets
Roche wins FDA approval for first at-home thyroid eye disease therapy
The approval brings a self-administered option to patients with thyroid eye disease.
Benzinga · +14 outlets
Base editing faces a regulatory reckoning after a decade of promise
The field's move into the clinic is testing regulators, highlighted by FDA clearance of a personalized CRISPR therapy.
The Clinical Trial Vanguard · +1 outlets
Next-gen RNAi drugmaker City Therapeutics prices $200M IPO
Proceeds will support three RNAi medicines in or nearing clinical testing and research into extrahepatic delivery.
Biopharmadive · +4 outlets
Regenxbio shares slide after FDA clinical hold on gene therapy; BofA keeps buy rating
The regulatory hold marks a setback for the company's gene therapy program despite analyst support.
Stocktwits · +1 outlets
Biotech analysts: hedge fund unwind is biggest in five years, only M&A can stop it
Sector analysts see a sharp pullback in hedge fund biotech exposure as a defining market dynamic.
BigGo Finance · +1 outlets
FDA announces new initiative for rare diseases
The agency unveiled a program aimed at advancing development of rare disease treatments.
Drug Discovery News · +14 outlets
Mankind Pharma to acquire Belgian biotech for cancer-care innovation
The deal expands the Indian drugmaker's oncology pipeline through a European acquisition.
VCCircle · +14 outlets
Nodexus-backed SimBioSys gets FDA clearance for Nvidia-powered breast cancer recurrence tool
The MRI-derived software aims to predict breast cancer recurrence to guide treatment decisions.
Fierce Biotech
PRIMA implant restores sight in patients with macular degeneration
The device offers a first potential vision-restoring option for geographic atrophy, which affects over 5 million people globally.
MIT Technology Review